Gastroenterology and Hepatology

Track25:Hepatitis D: The Silent Epidemic in Hepatology

Hepatitis D, caused by the Hepatitis D virus (HDV), is one of the most severe and often overlooked forms of viral hepatitis. This virus can only infect individuals already infected with Hepatitis B virus (HBV), making it a co-infection that accelerates liver disease progression. Known as the “silent epidemic,” Hepatitis D can lead to chronic liver disease, cirrhosis, and a significantly increased risk of hepatocellular carcinoma (HCC).

This session will focus on the pathophysiology, diagnosis, and management of Hepatitis D, shedding light on the global prevalence and clinical challenges it presents. Special attention will be given to the epidemiology, genetic characteristics, and clinical outcomes associated with HDV infection, particularly in regions with high HBV endemicity.

Discussions will also include current treatment options, such as pegylated interferon and the search for novel antiviral agents. As HDV is often underdiagnosed, the session will emphasize the importance of early detection, screening methods, and public health initiatives. The development of an effective Hepatitis D vaccine remains a priority, and the track will provide the latest updates on vaccine research.

Attendees will gain valuable insights into managing this deadly co-infection and its long-term impact on liver health.